Actinium Pharma

Actinium is developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently investigating therapies in #AML #BMT $ATNM

[Actinium Pharma @ActiniumPharma]

This week at #SNMMI26, Actinium presented new ATNM-400 data in NSCLC and prostate cancer, further supporting its differentiated profile across multiple solid tumor settings.

Thank you to everyone who met with our team in LA. We look forward to continuing the conversation. $ATNM

[Actinium Pharma @ActiniumPharma]

#SNMMI26 recap: new data on ATNM-400 in prostate cancer demonstrated ATNM-400 remains active in prostate cancer cells and tumors resistant to all three approved ARPIs, directly targeting the point of failure for a high proportion of mCRPC patients. https://t.co/K9je9odEE7 $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium Pharmaceuticals presented new preclinical ATNM-400 data at #SNMMI26, showing activity across KRAS- and EGFR-mutant NSCLC models and supporting its development as a potential mutation-agnostic backbone for the broader NSCLC market. https://t.co/Tf7ZoXINoh $ATNM @SNM_MI

[Actinium Pharma @ActiniumPharma]

Actinium appointed accomplished oncology expert Steffen Heeger MD, MSc as CMO to drive rejuvenated pipeline development of Actimab-A, ATNM-400, and Iomab-ACT as the company advances toward key data readouts and expanded clinical trials in 2H:2026. https://t.co/rA8kzcgawo $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium will present ATNM-400 data in prostate cancer, showing activity across PSMA-high, PSMA-low and PSMA-negative models, expanding potential utility beyond limitations of PSMA-targeted therapies.

June 2, 2026 | 11:30 am–12:15 pm PT

https://t.co/WI4sjqCLOi $ATNM #SNMMI26

[Actinium Pharma @ActiniumPharma]

Actinium will present ATNM-400 data in NSCLC at #SNMMI26, demonstrating mutation-agnostic anti-tumor activity in KRAS-mutated models, addressing key resistance mechanisms to EGFR and KRAS-targeted therapies. More: https://t.co/WI4sjqCLOi $ATNM

June 2, 2026 | 11:30 am–12:15 pm PT

[Actinium Pharma @ActiniumPharma]

Actinium will present preclinical radioconjugation data at #SNMMI26, supporting optimization of chelator-to-antibody ratio to improve tumor targeting, internalization and pharmacokinetics of 225Ac-labeled antibodies: https://t.co/WI4sjqCLOi $ATNM

May 31, 2026 | 7:30–8:00 pm PT

[Actinium Pharma @ActiniumPharma]

Actinium will showcase ATNM-400 and supporting radioconjugation science across three abstracts at #SNMMI26 next week in Los Angeles.

The presentations span solid tumor activity and antibody engineering work tied to next-generation 225Ac radiotherapies.

May 30–June 2, 2026 $ATNM

[Actinium Pharma @ActiniumPharma]

#SNMMI26 reminder: Actinium will present three abstracts highlighting ATNM-400 and its radioconjugate optimization platform May 30–June 2 in LA.

Data span NSCLC, prostate cancer and radiochemistry advancements supporting next-generation targeted radiotherapies. $ATNM

[Actinium Pharma @ActiniumPharma]

ICYMI: Actinium announced three upcoming #SNMMI26 presentations highlighting ATNM-400 across NSCLC and prostate cancer, plus radioconjugate optimization data supporting its development.

May 31 & June 2, 2026 | Los Angeles, CA

Details: https://t.co/WI4sjqCLOi $ATNM

[Actinium Pharma @ActiniumPharma]

Meaningful conversations throughout the week at #AACR26 in San Diego with our team in action discussing preclinical data on ATNM-400 demonstrating pan-tumor activity across prostate, lung & breast cancer models, with researchers and clinicians across the oncology community. $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium announced compelling pan-tumor data for ATNM-400 demonstrating broad efficacy across prostate, lung, and breast cancer models at #AACR26.

Read more: https://t.co/0exe7xZaZx $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium highlighted data presented at #AACR26 supporting transcriptional reprogramming as a central mechanism driving the mutation-agnostic anti-leukemic activity of Actimab-A in acute myeloid leukemia.

Read more: https://t.co/9uLvM1pBPK $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium announced ATNM-400 data demonstrating potent efficacy in triple-negative breast cancer and ability to overcome endocrine and HER2-targeted therapy resistance, being presented at #SABCS25, Dec. 10‑14, 2025 in Texas.

Read the press release: https://t.co/7a9A1JlALp $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at #SNMMI25. Read the press release: https://t.co/HH547lBg7g $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center (@UTSWMedCenter). Read the press release: https://t.co/84SVsmNsQF $ATNM #utswmed #radiotherapy

[Actinium Pharma @ActiniumPharma]

Wrapping up an incredible #AACR25 and pleased by the great response to our ATNM-400 & Actimab-A posters received. Thank you to everyone who engaged.

Both of our abstracts can be found here: https://t.co/hCXwniAxix $ATNM #AACR #Radiotherapy

[Actinium Pharma @ActiniumPharma]

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting. https://t.co/W90UTASYUX $ATNM #AACR25

[Actinium Pharma @ActiniumPharma]

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the #AACR25. https://t.co/zMTI4Fc0pt $ATNM

[Actinium Pharma @ActiniumPharma]

Actinium is looking forward to presenting ATNM-400 data at #AACR25 today. The abstract includes results from in vitro and in vivo studies, including biodistribution imaging and efficacy analyses with various dose levels of ATNM-400. https://t.co/pxgHPIV0zT $ATNM